FDA’s Drug Chief Latest to Depart During ‘Challenging Times’

Jacqueline Corrigan-Curay, the FDA’s acting top drug regulator, is stepping down from her post after serving at the agency for more than eight years, according to internal email obtained by Bloomberg Law.

Corrigan-Curay announced Monday in an email to the Center for Drug Evaluation and Research that she will retire from the agency in July after “considerable reflection.”

“This decision has been incredibly challenging, as I deeply value our collective achievements and recognize that no other place offers the same opportunities to advance public health alongside such smart, talented, and supportive colleagues,” Corrigan-Curay said in the email. “Many of you worked closely with me in my previous role, and as acting director, l’ve had even more chances to learn from you and make crucial decisions to improve patient health. Your expertise and dedication have been invaluable.”

The FDA has seen a significant overhaul under President Donald Trump and his pick to lead the agency, Marty Makary. A handful of long-time officials have left since January, including Peter Marks, the former director of the Center for Biologics Research and Evaluation; Jim Jones, head of Human Foods Program, and Michael Rogers, the former associate commissioner of inspections and investigations.

Corrigan-Curay became CDER’s acting director after former top drug chief, Patrizia Cavazzoni, departed the FDA in January.

She previously served as CDER’s principal deputy center director since July 2021. She joined the FDA in October 2016 as CDER’s director for the Office of Medical Policy, where she led the development, coordination, and implementation of medical policy programs and strategic initiatives, according to the agency.

Corrigan-Curay said the decision to retire was “difficult” due to the support she’s received from the CDER staff. She’s confident, however, that “CDER’s strength isn’t defined by any single individual,” and that she will “leave knowing CDER is in capable hands.”

“What has made this decision so difficult for me is all of you, “ she said in the email. “Your unwavering support, especially during recent challenging times, has been humbling. I do not mean to let anyone down, but I believe I need to follow my instincts.”

Corrigan-Curay said she will be at the FDA for several more weeks to ensure a smooth transition.